Applied Therapeutics, Inc.
appliedtherapeutics.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2025 10-Q, filed Nov 13, 2025. Its latest SEC filing is a SCHEDULE 13G/A from Feb 17, 2026.
10-Q for Q3 FY2025, filed Nov 13, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Develops drug candidates targeting aldose reductase for rare metabolic diseases, diabetic heart disease and diabetic eye disease.
10-K for FY2024, filed Apr 15, 2025We are a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates against molecular targets in…View ↗
Our lead candidate, AT-007 (also called govorestat) is a novel central nervous system, or CNS, penetrant aldose reductase inhibitor ("ARI")…View ↗
AT-001 (also called caficrestat) is a novel ARI with broad systemic exposure and peripheral nerve permeability that we were developing for…View ↗
AT-003 is a novel ARI designed to cross through the back of the eye when dosed orally, and has demonstrated strong retinal penetrance, for…View ↗
How Did They Make Money?
Receives an upfront license payment, payments for research and development work, milestone payments when specified clinical or regulatory goals are reached, and royalties on product sales under its European license agreement.
10-K for FY2024, filed Apr 15, 2025The Company has entered into an agreement to license its intellectual property, or IP, related to Galactosemia and SORD to develop…View ↗
On January 3, 2023, the Company entered into an Exclusive License and Supply Agreement (the “Advanz Agreement”) with Mercury Pharma Group…View ↗
Advanz Pharma is required to use commercially reasonable efforts to launch and commercialize the Licensed Products in the major markets in…View ↗
$455K
-
10-K for FY2024, filed Apr 14, 2025
$455K ↗
Who Were Their Customers?
Advanz Pharma holds exclusive European commercialization rights for the company’s drug candidate govorestat and receives research and development work and product supply from the company.
10-K for FY2024, filed Apr 15, 2025On January 3, 2023, the Company entered into an Exclusive License and Supply Agreement (the “Advanz Agreement”) with Mercury Pharma Group…View ↗
Did Revenues Turn Into Profits?
No. It lost $105.6M in FY2024.
10-K for FY2024, filed Apr 14, 2025
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2025, filed Nov 13, 2025
−$19MView ↗
- ▼ −72% (Loss)
- vs −$68.6M in Q3 FY2024
-
Feb 3, 2026
Applied Therapeutics became a wholly owned subsidiary after acquisition
The acquisition was completed, and Applied said its shares would no longer be listed on Nasdaq.
Sources
8-K, filed Feb 3, 2026
On February 3, 2026, Purchaser irrevocably accepted for payment all Shares validly tendered pursuant to the Offer and not validly withdrawn…View ↗
-
Dec 12, 2025
Cycle Pharmaceuticals agreed to acquire Applied Therapeutics
The agreement provided for cash at closing plus contingent value rights tied to regulatory and sales milestones.
Sources
8-K, filed Dec 12, 2025
On December 11, 2025, Applied Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the…View ↗
-
Nov 20, 2025
Applied began a strategic review and planned a workforce reduction
The company said it was exploring strategic alternatives and reducing its workforce by approximately 46%.
Sources
8-K, filed Nov 20, 2025
In connection with the evaluation of strategic alternatives, the Company is reducing the Company’s workforce by approximately 46%, in…View ↗
-
Nov 13, 2025
Executive Chairman John Johnson resigned
Sources
8-K, filed Nov 13, 2025
On November 9, 2025, John H. Johnson, Executive Chairman of the Company’s board of directors (the “Board”), provided notice of his…View ↗
Who Did They Compete With?
Competes with Glycomine
10-K for FY2024, filed Apr 15, 2025There are currently no therapies approved to treat PMM2-congenital disorder of glycosylation. Recently, Glycomine, Inc., a biotech company…View ↗
Loading...
